Topical Semisolid Drug Product Critical Quality Attributes with Relevance to Cutaneous Bioavailability and Pharmacokinetics: Part I—Bioequivalence of Acyclovir Topical Creams
Pharmaceutical Research · 2024
DOI: 10.1007/s11095-024-03736-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Y H Mohammed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutics Research Centre, Frazer Institute, The University of Queensland, Brisbane, Australia. Y.Mohammed@uq.edu.au. Hauptthemen laut MEDLINE: Acyclovir, Skin Cream, Skin Absorption, Biological Availability. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Food and Drug Administration, The University of Queensland.
Abstract (Originalsprache)
Purpose
To develop a toolkit of test methods for characterizing potentially critical quality attributes (CQAs) of topical semisolid products and to evaluate how CQAs influence the rate and extent of active ingredient bioavailability (BA) by monitoring cutaneous pharmacokinetics (PK) using an In Vitro Permeation Test (IVPT).
Methods
Product attributes representing the physicochemical and structural (Q3) arrangement of matter, such as attributes of particles and globules, were assessed for a set of test acyclovir creams (Aciclostad® and Acyclovir 1A Pharma) and compared to a set of reference acyclovir creams (Zovirax® US, Zovirax® UK and Zovirax® Australia). IVPT studies were performed with all these creams using heat-separated human epidermis, evaluated with both, static Franz-type diffusion cells and a flow through diffusion cell system.
Results
A toolkit developed to characterize quality and performance attributes of these acyclovir topical cream products identified certain differences in the Q3 attributes and the cutaneous PK of acyclovir between the test and reference sets of products. The cutaneous BA of acyclovir from the set of reference creams was substantially higher than from the set of test creams.
Conclusions
This research elucidates how differences in the composition or manufacturing of product formulations can alter Q3 attributes that modulate myriad aspects of topical product performance. The results demonstrate the importance of understanding the Q3 attributes of topical semisolid drug products, and of developing appropriate product characterization tests. The toolkit developed here can be utilized to guide topical product development, and to mitigate the risk of differences in product performance, thereby supporting a demonstration of bioequivalence (BE) for prospective topical generic products and reducing the reliance on comparative clinical endpoint BE studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Therapeutics Research Centre, Frazer Institute, The University of Queensland, Brisbane, Australia. Y.Mohammed@uq.edu.au.
- School of Pharmacy, The University of Queensland, Woolloongabba, QLD, 4102, Australia. Y.Mohammed@uq.edu.au.
- Therapeutics Research Centre, Frazer Institute, The University of Queensland, Brisbane, Australia.
- Institute of Pharmaceutical Technology, Goethe University, Frankfurt, Germany.
- Curtin Medical School, Curtin University, Perth, WA, Australia.
- Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
Förderung
- U.S. Food and Drug Administration
- The University of Queensland
Zitieren
APA
Mohammed, Y. H., Namjoshi, S. N., Jung, N., Windbergs, M., Benson, H. A. E., Grice, J. E., Raney, S. G., & Roberts, M. S. (2024). Topical Semisolid Drug Product Critical Quality Attributes with Relevance to Cutaneous Bioavailability and Pharmacokinetics: Part I—Bioequivalence of Acyclovir Topical Creams. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03736-9
Vancouver
Mohammed YH, Namjoshi SN, Jung N, Windbergs M, Benson HAE, Grice JE, et al. Topical Semisolid Drug Product Critical Quality Attributes with Relevance to Cutaneous Bioavailability and Pharmacokinetics: Part I—Bioequivalence of Acyclovir Topical Creams. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03736-9
BibTeX
@article{Mohammed2024,
author = {Mohammed, Y H and Namjoshi, S N and Jung, N and Windbergs, M and Benson, H A E and Grice, J E and Raney, S G and Roberts, M S},
title = {Topical Semisolid Drug Product Critical Quality Attributes with Relevance to Cutaneous Bioavailability and Pharmacokinetics: Part I—Bioequivalence of Acyclovir Topical Creams},
journal = {Pharmaceutical Research},
year = {2024},
doi = {10.1007/s11095-024-03736-9}
}
EUVIMED